(Albany, US) DelveInsight has launched a new report on Sarcopenia Pipeline
“Sarcopenia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sarcopenia market. A detailed picture of the Sarcopenia pipeline landscape is provided, which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces in-depth Sarcopenia commercial assessment and clinical assessment of the Sarcopenia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases. The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic and behavioral factors. In 2016, an ICD-10-CM (International Statistical Classification of Diseases and Related Health Problems, revision 10, clinical modifications) code was introduced for sarcopenia, which acknowledged it as a disease for the first time. Treatments have focused mostly on extrinsic approaches such as exercise and diet, but recent scientific advances have brought greater attention to additional treatment options. Trials with various agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options. Till date, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. To achieve that, increased awareness of sarcopenia is of great importance to begin reaching consensus on diagnosis and to contribute to finding a cure for this condition.
View Free Sample Page:- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight
Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials. Some of the potential candidates are elaborated below. Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Preclinical data demonstrated that Sarconeos (BIO101) for the treatment of sarcopenia has beneficial effects on muscle function and increases muscle strength and mobility in animal models. It activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS). Novartis “breakthrough” drug bimagrumab is currently being evaluated for the treatment of sarcopenia and has demonstrated good safety and efficacy profile in phase III trials. Bimagrumab is a human monoclonal antibody that binds to type II activin receptors and prevents the binding of its ligands (e.g., myostatin, activin A). These ligands normally act as inhibitors of muscle growth and protein anabolism; bimagrumab lifts this inhibition and can increase muscle mass in young and older adults. However, one of its other major trials targeting sporadic Inclusion Body Myositis (sIBM) using the same drug candidate failed to meet its primary endpoints, and the program was discontinued in this disease in 2016. There have been no major trial related updates since 2018. Amazentis’s AMAZ-02 is an oral formulation of urolithin A, a naturally occurring metabolite that has been shown to improve mitochondrial and muscle function through a process known as mitophagy. . Results from phase I studies indicate that urolithin A stimulates mitochondrial biogenesis in the same manner as exercise, and it is the only known compound able to reestablish cell’s ability to recycle defective mitochondria according to the researchers. Mitochondrial biogenesis is the process by which cells increase mitochondrial mass, this happens naturally in younger people but with age the body starts to lose the energy to clean up leftovers and dysfunctional mitochondria which could lead to eventual weakening of tissues and loss of muscle mass/sarcopenia. In April 2019 Nestlé Health Science announced that it has entered into a global strategic partnership with Amazentis to develop Urolithin A. Sarcopenia is a growing socio-economic burden due to the ongoing demographic shift and the aging of most societies, with no viable treatment to meet the global need. The complexity is further added because no endpoint has been approved yet for the registration of a drug for sarcopenia or other muscle-wasting condition. However, the silver lining is that the health authorities are moving closer to accepting physical performance-based and patient-reported outcome assessments for use in drug trials. Overall, the muscle atrophy market is poised at a critical juncture. Antimyostatin agents have been in clinical trials for more than a decade, and SARMs even longer, with little to present.
The expected launch of emerging therapies is expected to create a significant impact on the market size during the forecast period (2020–2030).
Emerging therapies included in the report
- Sarconeos: Biophytis
- Bimagrumab: Novartis
- LY2495655: Eli Lily
- Trevogrumab: Regeneron Pharmaceuticals/ Sanofi
- PF 1801: Immunoforge
Sarcopenia Report Scope
- The Sarcopenia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Sarcopenia across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Sarcopenia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Sarcopenia research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Sarcopenia.
Download free sample page:- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight
Table of content
1. Report Introduction
3. Sarcopenia Current Treatment Patterns
4. Sarcopenia – DelveInsight’s Analytical Perspective
6. Sarcopenia Late Stage Products (Phase-III)
7. Sarcopenia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sarcopenia Discontinued Products
13. Sarcopenia Product Profiles
14. Sarcopenia Key Companies
15. Sarcopenia Key Products
16. Dormant and Discontinued Products
17. Sarcopenia Unmet Needs
18. Sarcopenia Future Perspectives
19. Sarcopenia Analyst Review
21. Report Methodology
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States